Discover how tirzepatide benefits heart failure in obesity, and see why those with higher BMI may gain even more benefits.

Eli Lilly (NYSE:LLY) announced Thursday that its diabetes therapy, Mounjaro (tirzepatide), succeeded in a late-stage trial ...

Tirzepatide helps obese adults lose over 15% of body weight in 52 weeks—and retain much of it even six months after stopping ...

A new study reports that mice shed about 20% of their body weight and saw their breast cancer tumors decrease after getting ...

Baseline BMI may play a significant role in improving exercise capacity, body weight and BP among patients with HF with ...

A variety of GLP-1 drugs that were developed to treat Type 2 diabetes, including Novo Nordisk’s Ozempic, have secured label ...

Tirzepatide yielded greater cardiometabolic benefits, especially in total cholesterol, LDL cholesterol, and weight loss, among women than men.

Eli Lilly said it believes the new data bolsters the case for Mounjaro to be prescribers’ first choice for patients with Type ...

Key TakeawaysThe weight-loss drug tirzepatide reduced both body fat and tumor growth in obese mice with breast cancer. Tumor ...

New study reveals weight-loss drugs help during treatment but weight returns rapidly after stopping. Here's what they found.

Weight-loss drugs like semaglutide and tirzepatide may help shrink waistlines, but new research shows they fail to boost ...

Check your insurance plan to be sure, but providers don’t often cover tirzepatide for weight loss. If they do, there might be some requirements you need to meet or copays and deductibles, so you ...